Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 15/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16129728 | 0.91 | ENPP2 (0.38) | ENPP2KCNH2GRM5 | |
| SCHEMBL16100138 | 0.89 | ENPP2 (0.42) | ENPP2KCNH2 | |
| SCHEMBL16094524 | 0.85 | TACR1 (0.34) | CYP4F2CYP4A11FAAH | |
| SCHEMBL16099316 | 0.84 | NPC1 (0.39) | ENPP2FAAHGRM5 | |
| SCHEMBL16100641 | 0.83 | FAAH (0.45) | ENPP2KCNH2FAAHGRM5 | |
| SCHEMBL16093608 | 0.81 | ENPP2 (0.44) | ENPP2KCNH2FAAH | |
| SCHEMBL16103196 | 0.80 | ENPP2 (0.41) | ENPP2KCNH2 | |
| SCHEMBL16093662 | 0.80 | ENPP2 (0.41) | ENPP2KCNH2 | |
| SCHEMBL16100053 | 0.79 | ENPP2 (0.41) | ENPP2KCNH2 | |
| SCHEMBL16100467 | 0.79 | GRIN2B (0.41) | ENPP2GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970302-A1 | S1P AND/OR ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | claimed |
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2016-02-11 | — | — | US | disclosed |
| EP-2970302-A1 | S1P AND/OR ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150125422-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-05-07 | — | — | US | disclosed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150125422-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, GOT1 | ENPP2 3133/4885KCNH2 3720/4885CYP4F2 273/4885 |
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | ENPP2 1/4885KCNH2 2017/4885CYP4F2 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.